Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Accumulated Expenses (2019 - 2025)

Volitionrx (VNRX) has disclosed Accumulated Expenses for 7 consecutive years, with $4.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 31.75% year-over-year to $4.6 million, compared with a TTM value of $4.6 million through Sep 2025, up 31.75%, and an annual FY2024 reading of $3.5 million, down 11.5% over the prior year.
  • Accumulated Expenses was $4.6 million for Q3 2025 at Volitionrx, up from $4.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.6 million in Q3 2025 and bottomed at $2.7 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $3.5 million, with a median of $3.4 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses fell 24.98% in 2022, then skyrocketed 36.78% in 2023.
  • Year by year, Accumulated Expenses stood at $3.8 million in 2021, then fell by 24.98% to $2.9 million in 2022, then skyrocketed by 36.78% to $3.9 million in 2023, then dropped by 11.5% to $3.5 million in 2024, then skyrocketed by 31.87% to $4.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for VNRX at $4.6 million in Q3 2025, $4.4 million in Q2 2025, and $3.7 million in Q1 2025.